AVTX
NASDAQ · Biotechnology
Avalo Therapeutics Inc
$18.88
-0.57 (-2.93%)
Open$19.12
Previous Close$19.45
Day High$19.33
Day Low$18.34
52W High$24.27
52W Low$8.41
Volume—
Avg Volume711.6K
Market Cap1.04B
P/E Ratio—
EPS$-6.04
SectorBiotechnology
Analyst Ratings
Strong Buy
21 analysts
Price Target
+74.3% upside
Current
$18.88
$18.88
Target
$32.91
$32.91
$27.78
$32.91 avg
$47.11
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 243.2K | 1.64M | 36.29M |
| Net Income | -322,715,665 | -1,957,170,475 | 8.09M |
| Profit Margin | -132,642.4% | -126,010.3% | 22.3% |
| EBITDA | -299,300,109 | -1,916,004,740 | 9.50M |
| Free Cash Flow | — | — | 4.67M |
| Rev Growth | -85.2% | -85.2% | +16.8% |
| Debt/Equity | 0.03 | 0.03 | 0.47 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |